Trial Profile
Low Dose Plerixafor Plus G-CSF Efficiency in Mobilizing Stem Cells From Lymphoma and Myeloma Patients for Autologous Peripheral Blood Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- 01 Dec 2019 Status changed from recruiting to completed as per results published in the Transfusion
- 16 Aug 2017 New trial record